MIT's implantable device could end daily insulin shots for diabetes patients

MIT researchers, working with the Technion, have developed an implantable device that could replace daily insulin injections for diabetes patients. The technology uses encapsulated insulin-producing cells to regulate blood sugar levels automatically. Early tests in animals have shown promising results, with the device maintaining healthy glucose levels for extended periods. The new device protects insulin-producing cells from immune rejection while keeping them healthy with an on-board oxygen generator. In tests, it functioned for at least 90 days in rats and mice, successfully controlling blood sugar levels. Cells derived from induced pluripotent stem cells also demonstrated some ability to regulate glucose in mice.

The researchers improved the device's durability by enhancing its waterproofing, resilience, and power delivery. These upgrades extended its lifespan, with the goal of making it last up to two years or longer in future versions. Beyond diabetes, the technology could potentially deliver other therapeutic cells, such as those producing antibodies or enzymes. Funding for the project came from Breakthrough TID, the Leona M. and Harry B. Helmsley Charitable Trust, the NIH, and a Koch Institute Support Grant. The next phase involves testing the device in human patients to further extend its functional duration.

If successful in humans, the implant could eliminate the need for frequent insulin injections and blood sugar monitoring. The device has already proven effective in animal models, maintaining stable glucose levels for months. Further development aims to refine its longevity and expand its medical applications.